Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Research & Development (2017 - 2025)

Arcus Biosciences has reported Research & Development over the past 9 years, most recently at $121.0 million for Q4 2025.

  • Quarterly results put Research & Development at $121.0 million for Q4 2025, up 19.8% from a year ago — trailing twelve months through Dec 2025 was $523.0 million (up 16.74% YoY), and the annual figure for FY2025 was $523.0 million, up 16.74%.
  • Research & Development for Q4 2025 was $121.0 million at Arcus Biosciences, down from $141.0 million in the prior quarter.
  • Over the last five years, Research & Development for RCUS hit a ceiling of $141.0 million in Q3 2025 and a floor of $50.6 million in Q4 2021.
  • Median Research & Development over the past 5 years was $83.0 million (2023), compared with a mean of $92.8 million.
  • Biggest five-year swings in Research & Development: surged 186.87% in 2021 and later dropped 8.11% in 2022.
  • Arcus Biosciences' Research & Development stood at $50.6 million in 2021, then surged by 58.14% to $80.0 million in 2022, then grew by 16.25% to $93.0 million in 2023, then rose by 8.6% to $101.0 million in 2024, then grew by 19.8% to $121.0 million in 2025.
  • The last three reported values for Research & Development were $121.0 million (Q4 2025), $141.0 million (Q3 2025), and $139.0 million (Q2 2025) per Business Quant data.